LT-001 (Leadingtac)

N/A

Report date: 2025/03/28 10:21:14
NME

Base Information

Drug NameLT-001 (Leadingtac)
Drug Alias NameLT-001
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 degraders
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsAutoimmune DiseasesPsoriasisDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesShanghai Leadingtac Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Leadingtac Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesPsoriasisDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A